ClinicalTrials.gg
CompletedNCT02031653Updated Dec 2, 2019

Comparison Between Invasive Pressure Flow Study and Non-invasive Penile Cuff Test

An observational study in Bladder Outlet Obstruction and Pressure Flow Study, sponsored by Samsung Medical Center. Completed at 1 site in Korea, Republic of. Open to male participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2019-12-02.

Sponsored by Samsung Medical Center · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
335
Ages
40 Years and older
Sex
Male
01

Study summary

To provide evidence of promising tests to noninvasively diagnose bladder outlet obstruction (BOO) in men with benign prostatic hyperplasia.

  1. Penile cuff test provides a means of obtaining a urodynamic diagnosis with a high level of accuracy without the morbidity and expense of invasive Pressure flow study.
  2. Penile cuff test may be particularly useful in the counseling of patients prior to benign prostatic hyperplasia operation. Patients diagnosed as obstructed following a penile cuff test can be reassured that surgery has a high chance of resulting in symptomatic benefit
02

Conditions studied

  • Bladder Outlet Obstruction
  • Pressure Flow Study

Keywords

  • Penile Cuff Test
03

In context

Urinary Bladder Neck Obstruction

46 studies on the registry are indexed under Urinary Bladder Neck Obstruction; 10 are open to participants now.

This study's enrollment of 335 is above the median of 165 across 14 observational studies indexed under Urinary Bladder Neck Obstruction.

Browse Urinary Bladder Neck Obstruction studies →

Lead sponsor

Samsung Medical Center is the lead sponsor of 1,011 studies on the registry; 152 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Male patients with Low Urinary Tract Symptoms over 6 months.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male patients with Low Urinary Tract Symptoms over 6 months. (International prostatic symptom score >= 12)
  2. Patients scheduled to have pressure flow study.
  3. Able to give fully

Exclusion criteria

Exclusion Criteria:

  1. Patients with urologic such as prostate cancer and bladder cancer
  2. Patients underwent urethral, prostate surgery
  3. Patients with urethral stricture or bladder diverticulum or bladder neck contracture
  4. seems not to be appropriate to this study by the decision of investigators because of any other reasons
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
335 participants (actual)
Patient registry
No

Groups and cohorts

  • Study Group
06

What researchers measure

Primary outcomes

  1. The Positive/Negative Predictive Value of Penile cuff test

    Time frame: 5 hours

  2. The proportion comparison of Good responder between obstructed and unobstructed patients in penile cuff test

    good responder: The reduction in the International Prostatic Symptom Scores of more than 50% from the initial scores 3 months after operation.

    Time frame: up to 3 months

Secondary outcomes

  1. The correlation of intra-vesical Pressure between Pressure flow study and penile cuff test

    Time frame: 5 hours

  2. The difference of Pain visual analogue scale score between two diagnostic tests

    Time frame: 5 hours

  3. The categorical change of penile cuff test normogram after BPH operation

    Time frame: up to 3 months

  4. The PSA level change after benign prostatic hyperplasia operation in obstructed and non-obstructed patients.

    Time frame: up to 3 months .

  5. The changes of International Prostatic Symptom Scores after BPH operation.

    Time frame: up to 3 months

07

Study locations

1 site
  • Samsung Medical Center
    Seoul,, 130-710, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2014, a primary completion of Jul 2017 and a completion of Dec 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2014
First posted
Jan 9, 2014
Start
Jan 2014
Primary completionActual
Jul 2017
CompletionActual
Dec 2017
Last update
Dec 2, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02031653
Responsible party
KYU-SUNG LEE (professor, Samsung Medical Center) — Principal investigator
First posted
Jan 9, 2014
Start date
Jan 2014
Primary completion
Jul 2017
Completion
Dec 2017
Last update
Dec 2, 2019

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion